Abstract
Background: Mathematical modelling may aid in understanding the complex interactions between injury and immune response in critical illness.
Methods: We utilize a system biology model of COVID-19 to analyze the effect of altering baseline patient characteristics on the outcome of immunomodulatory therapies. We create example parameter sets meant to mimic diverse patient types. For each patient type, we define the optimal treatment, identify biologic programs responsible for clinical responses, and predict biomarkers of those programs.
Findings: Model states representing older and hyperinflamed patients respond better to immunomodulation than those representing obese and diabetic patients. The disparate clinical responses are driven by distinct biologic programs. Optimal treatment initiation time is determined by neutrophil recruitment, systemic cytokine expression, systemic microthrombosis and the renin-angiotensin system (RAS) in older patients, and by RAS, systemic microthrombosis and trans IL6 signalling for hyperinflamed patients. For older and hyperinflamed patients, IL6 modulating therapy is predicted to be optimal when initiated very early (<4 th day of infection) and broad immunosuppression therapy (corticosteroids) is predicted to be optimally initiated later in the disease (7 th – 9 th day of infection). We show that markers of biologic programs identified by the model correspond to clinically identified markers of disease severity.
Interpretation: We demonstrate that modelling of COVID-19 pathobiology can suggest biomarkers that predict optimal response to a given immunomodulatory treatment. Mathematical modelling thus constitutes a novel adjunct to predictive enrichment and may aid in the reduction of heterogeneity in critical care trials.
Funding: C.V. received a Marie Skłodowska Curie Actions Individual Fellowship (MSCA-IF-GF-2020-101028945). R.K.J.’s research is supported by R01-CA208205, and U01-CA 224348, R35-CA197743 and grants from the National Foundation for Cancer Research, Jane’s Trust Foundation, Advanced Medical Research Foundation and Harvard Ludwig Cancer Center. No funder had a role in production or approval of this manuscript.
Keywords: COVID-19; NMF; Systems biology; clustering; heterogeneity of treatment effect; modelling; non-negative matrix factorization; principal component analysis; treatment.
【저자키워드】 COVID-19, Treatment, modelling, Systems biology, non-negative matrix factorization, principal component analysis, Clustering, NMF, heterogeneity of treatment effect, 【초록키워드】 Treatment, Critical illness, Corticosteroids, immune response, therapy, Biomarker, Biomarkers, Critical care, disease severity, neutrophil, Infection, immunomodulation, IL6, Immunosuppression, Systems biology, outcome, heterogeneity, RAS, non-negative matrix factorization, principal component analysis, renin-angiotensin system, Characteristics, immunomodulatory, Research, Patient, Model, Mathematical modelling, Clustering, Trust, expression, Critical, predict, trials, biologic, Microthrombosis, marker, diabetic patients, angiotensin, Injury, older patients, Immunomodulatory therapies, Predictive, determined by, Principal component, reduction, Diabetic, System biology, Older, Renin, clinical response, individual, obese, foundation, approval, center, treatment initiation, manuscript, neutrophil recruitment, complex interaction, parameter, clinical responses, Curie, System, hyperinflamed, hyperinflamed patients, responsible, predicted, identify, example, clinically, the disease, supported, initiated, representing, driven by, respond, disparate, Action, baseline, hyperinflamed patient, modulating, systemic cytokine, 【제목키워드】 clinical trial, Strategy, respiratory, insight,